Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML

Feven Tameire(FuelCell Energy (United States)), Nandita Bose(FuelCell Energy (United States)), Ben J. Harrison(The University of Melbourne), Paulina M. Wojnarowicz(Memorial Sloan Kettering Cancer Center), Michael E. Stokes(FuelCell Energy (United States)), Nicholas Collette(FuelCell Energy (United States)), Kathryn Bieging-Rolett(Stanford University), Ashley LaCayo(FuelCell Energy (United States)), David Surguladze(Intellicell Biosciences (United States)), Kirk A. Staschke(Indiana University Health), Jeremy Drees(FuelCell Energy (United States)), Eric S. Lightcap, Sho Fujisawaa(FuelCell Energy (United States)), Crissy Dudgeon(Rutgers, The State University of New Jersey)
Blood
November 2, 2023
Cited by 3


Related Papers